Central 5-HT2(A) and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men

Psychopharmacology

Volumn 131, Issue 4, 1997, Pages 339-345

  Andrée, Bengt ^a   Halldin, Christer ^a   Vrijmoed De Vries, Maria ^b   Farde, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NV ORGANON   (Netherlands)

Author keywords

Antipsychotic drugs; Dopamine reccptors; Human brain; ORG 5222; PET; Positron emission tomography; Serotonin receptors; Sublingual administration

Indexed keywords

2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; 3 METHYLSPIPERONE C 11; CARBON 11; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PLACEBO; RACLOPRIDE; SEROTONIN 2A RECEPTOR; ANXIOLYTIC AGENT; ASENAPINE; DIBENZOXEPIN DERIVATIVE; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEOCORTEX; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SUBLINGUAL DRUG ADMINISTRATION; VERTIGO; BLOOD; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; SCINTISCANNING;

ADMINISTRATION, SUBLINGUAL; ADULT; ANTI-ANXIETY AGENTS; BRAIN; DIBENZOXEPINS; HUMANS; MALE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030610198     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050301     Document Type: Article

References (39)

1. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992) Do central untiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry Suppl 17:12 6
2. Baron JC, Martinot JL, Cumbon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99:463-472
3. Bergström M, Boëthius J, Eriksson L, Greitz T, Ribbe T, Widén L (1981) Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr 5:136 141
4. Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15:24s 29s
5. de Boer T, Berendsen H, Broekkamp CLE, Vrijmoed-de Vries MC, Vos RME, Tonnaer JADM, van Delft AML (1993) Org 5222. Drugs Future 18:1117 1123
6. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140 144
7. Chien YW (1994) Recent advances in noninvasive systemic delivery of pharmaceuticals and biopharmaceuticals. Drug Dev Industr Pharm 20:417 468
8. 2 receptor binding in schizophrenic patients treated with distinct classes of antipsychotic drugs. In: Shagass C (ed) Proc IVth World Congress of Biological Psychiatry. Elsevier, New York, pp 363 365
9. 2 dopamine receptor binding in the living human brain by PET. Science 231:258 261
10. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71 76
11. 2-dopamine receptors studied by PET a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696 708
12. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538 544
13. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538 544
14. 2-occupancy in clozapine treated patients. J Clin Psychiatry 55 [suppl B]:67 69
15. 2 receptor binding in risperidone treated schizophrenic patients. J Clin Psychopharmacol 15:19S 23S
16. 2 receptors. Prog Neuro-Psychopharmacol. Biol. Psychiatry 12:559 568
17. Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberger A, Solin O (1991) A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Nucl Med Biol 18: 871 881
18. 2 recognition sites. Brain Res 376:97 107
19. Kahn RS, Davidson M (1993) Serotonin, dopamine and their interactions in schizophrenia [editorial]. Psychopharmacology 112:S1 4
20. 125I]epidepride. Brain Res 609: 237 243
21. 2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex. J Neurosci 6:2941 2949
22. 2c, in depressive disorders: effect of medifoxamine: Encephale 20:427 435
23. 11C]raclopride binding. J Cereb Blood Flow Metab Raven Press, NY, p 643
24. 11C]raclopride binding in healthy young adults and schizophrenic patients reliability and age effects. Hum Psychopharmacol 7:157-165
25. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110:365-367
26. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449
27. 2 dopamine receptor occupancy in the living human brain a PET-study with risperidone. Psychopharmacology 110: 265 272
28. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology (in press)
29. 2 dopamine receptor occupancy. Psychiatry Res Neuroimaging (in press)
30. Pazos A, Probst A, Palacios JM (1987) Serotonin receptors in the human brain - IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21:123 139
31. 2-receptors in human brain. Brain Res 276:231-235
32. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717 719
33. Sitsen JMA, Farde L (1995) PET studies in the early clinical development of a new antipsychotic. In: Comar D (ed) PET for drug development and evaluation. Kluwer, Dordrecht, pp 67 71
34. Sitsen JMA, Vrijmoed-de Vries MC (1992) ORG 5222: preliminary clinical results. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, NY, pp 15-18
35. 2 receptor occupancy in schizophrenic patients. Biol Psychiatry 23:653-663
36. van Rossum JM (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn 160:492 494
37. Wagner HNJ, Burns HD, Dannals RF, Wong DF, Långström B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221:1264-1266
38. Wienhard K, Dahlbom M, Eriksson L, Michel C. Bruckbauer T, Pietrzyk U, Heiss W (1994) The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 18:110-118
39. Wong D, Wagner H, Dannals R, Links J, Frost J, Ravert H, Wilson A, Rosenbaum A, Gjedde A, Douglass K, Petronis J, Folstein M, Toung J, Burns H, Kuhar M (1984) Effects of age on dopamine and serotonin receptors measured by positron emission tomography in the living human brain. Science 226: 1393-1396